ARSB and melanoma: In this project, following treatment with recombinant human ARSB in the syngeneic B16F10 mouse model of subcutaneous melanoma and in the human A375 melanoma cell line, expression of CSPG4 declined significantly, suggesting another approach to inhibit CSPG4.